test

Available Trials

Latest Clinical Trials

10
19F-MRS (Magnetic Resonance Spectroscopy) Studies of in-vivo 5-Fluorouracil Pharmacokinetics with and without Bevacizumab in Patients with Liver Metastases from Adenocarcinoma of the Colon
Disease/Condition: Colon | Colon Cancer
Principal Investigator: Howard Hochster
A Multi-arm Phase I Safety Study of Nivolumab in Combination with Gemcitabine/Cisplatin, Pemetrexed/Cisplatin, Carboplatin/Paclitaxel, Bevacizumab Maintenance, Erlotinib, Ipilimumab or as Monotherapy in Subjects with Stage IIIB/IV Non-small Cell Lung Cancer
Disease/Condition: Lung
Principal Investigator: Scott Gettinger
A Multi-center pilot study of the effect of Sorafenib on Portal Pressure in Patients with Cirrhosis, Significant Portal Hypertension and Hepatocellular Carcinoma
Disease/Condition: Hepatocellular Carcinoma | Liver
Principal Investigator: Guadalupe Garcia-Tsao
A Phase 1 Dose Escalation Study of BMS-982470 (Recombinant Interleukin-21, rIL-21) in Combination with BMS-936558 (Anti-PD-1) in Subjects with Advanced or Metastatic Solid Tumors
Disease/Condition: Melanoma, skin
Principal Investigator: Mario Sznol
A Phase 1/2 Study of the Oral ALK/EGFR Inhibitor AP26113
Disease/Condition: Anus | Bladder | Bones and Joints | Brain and Nervous System | Breast - Female | Breast - Male | Cervix Uteri | Colon | Corpus Uteri | Esophagus | Eye and Orbit | Hodgkin's Lymphoma | Ill-Defined Sites | Kidney | Larynx | Lip, Oral Cavity and Pharynx | Liver | Lung | Lung Cancer | Melanoma, skin | Multiple Myeloma | Non-Hodgkin's Lymphoma | Other Digestive Organ | Other Endocrine System | Other Female Genital | Other Male Genital | Other Urinary | Ovary | Pancreas | Prostate | Rectum | Small Intestine | Soft Tissue | Stomach | Thyroid
Principal Investigator: Scott Gettinger
A Phase 1b Open-label Study to Evaluate the Safety and Tolerability of MEDI4736 in Combination with Tremelimumab in Subjects With Advanced Non-Small Cell Lung Cancer
Disease/Condition: Lung
Principal Investigator: Sarah Goldberg
A Phase I Dose Escalation Open-Label Safety, Pharmacokinetic and Pharmacodynamic Study to Determine the Recommended Phase II Dose of GSK1120212 Dosed in Combination with GSK2141795
Disease/Condition: Melanoma, skin
Principal Investigator: Joseph Paul Eder
A Phase I Dose Escalation Study Evaluating the Safety and Tolerability of GDC-0032 in Patients With Locally Advanced or Metastatic Solid Tumors And in Combination With Endocrine Therapy in Patients With Locally Advanced or Metastatic Hormone Receptor-Positive Breast Cancer
Disease/Condition: Anus | Bladder | Breast - Female | Breast - Male | Cervix Uteri | Colon | Esophagus | Kidney | Larynx | Liver | Lung | Other Digestive Organ | Other Endocrine System | Other Female Genital | Other Male Genital | Other Respiratory and Intrathoracic Organs
Principal Investigator: Lajos Pusztai
A Phase I Open label, Dose Finding Study of IMCgp100 in Patients with Advanced Malignant Melanoma
Disease/Condition: Melanoma, skin
Principal Investigator: Mario Sznol
A Phase I, Open-label, dose-escalation study of the safety and pharmacokinetics of MPDL3280A administered intravenously as a single agent to patients with locally advanced or metastatic solid tumors or hematologic malignancies
Disease/Condition: Bladder | Breast - Female | Colon | Esophagus | Kidney | Larynx | Lip, Oral Cavity and Pharynx | Lung | Melanoma, skin | Multiple Myeloma | Non-Hodgkin's Lymphoma | Other Digestive Organ | Other Male Genital | Pancreas | Prostate | Rectum | Soft Tissue | Stomach | Thyroid
Principal Investigator: Roy Herbst
A Phase I/II Study of A-dmDT390-bisFv (UCHT1) Fusion Protein in Patients with Surface CD3+ Malignant T Cell Diseases
Disease/Condition: Cancer | Non-Hodgkin's Lymphoma
Principal Investigator: Francine Foss
A Phase I/II Study of Cabazitaxel Combined with Abiraterone Acetate and Prednisone in Patients with Metastatic Castrate-Resistant Prostate Cancer (mCRPC) whose Disease has Progressed after Docetaxel Chemotherapy
Disease/Condition: Prostate
Principal Investigator: Daniel Petrylak
A Phase I/II Study of ISIS 481464, an Antisense Oligonucleotide Inhibitor of STAT3, Administered to Patients with Advanced Cancers
Disease/Condition: Lymphoid Leukemia
Principal Investigator: Joseph Paul Eder
A Phase I/II Study of the Combination of BKM120 and Bevacizumab, Glioblastoma Multiforme
Disease/Condition: Brain and Nervous System
Principal Investigator: Kevin Becker
A Phase I/II Study to Assess the Safety and Activity of Enhanced TCR Transduced Autologous T cells against Cancer-testis Antigens in Metastatic Melanoma
Disease/Condition: Melanoma, skin
Principal Investigator: Harriet Kluger
A Phase I/II, Open-label Study of Nivolumab Monotherapy or Nivolumab combined with Ipilimumab in Subjects with Advanced or Metastatic Solid Tumors
Disease/Condition: Breast - Female | Lung | Pancreas | Stomach
Principal Investigator: Joseph Paul Eder
A Phase I/IIa, First Time in human, open-label dose-escalation study of GSK2636771 in subjects with advanced solid tumors with PTEN deficiency
Disease/Condition: Brain and Nervous System | Breast - Female | Breast - Male | Breast Cancer (ER, PR, and HER2 negative) | Colon | Colorectal Cancer | Endometrial Cancer | Gastric Adenocarcinoma | Glioblastoma Multiforme | Head/ Neck Squamous Cell Carcinoma | Lip, Oral Cavity and Pharynx | Lung | Melanoma | Melanoma, skin | Non-Small Cell Lung Cancer (NSCLC) | Other Female Genital | Ovarian Cancer | Ovary | Prostate | Prostate Cancer | Rectum | Stomach
Principal Investigator: Joseph Paul Eder
A Phase Ib Multi-Cohort Study of MK-3475 in Subjects with Advanced Solid Tumors
Disease/Condition: Bladder | Breast - Female | Lip, Oral Cavity and Pharynx | Stomach
Principal Investigator: Lajos Pusztai
A Phase II Open Label Multicenter Study of PSMA ADC in Subjects with Castration-resistant Metastatic Prostate Cancer
Disease/Condition: Cancer | Prostate
Principal Investigator: Daniel Petrylak
A Phase II Study of Hsp90 Inhibitor AUY922 for the Treatment of Patients with Refractory Gastrointestinal Stromal Tumor
Disease/Condition: Cancer | Other Digestive Organ
Principal Investigator: Howard Hochster
A Phase II Study of MK-3475 in Patients with Metastatic Melanoma or Non-Small Cell Lung Cancer with Untreated Brain Metastases
Disease/Condition: Lung | Melanoma, skin
Principal Investigator: Harriet Kluger
A Phase II Trial of Carboplatin/Paclitaxel with and without Trastuzumab in HER2/neu+ Patients with Advanced orRecurrent Uterine Serous Papillary Cancer
Disease/Condition: Corpus Uteri
Principal Investigator: Alessandro Santin
A Phase II Trial of Response-Based Radiation Therapy for Pediatric Patients with Localized Central Nervous System Germ Cell Tumors (CNS GCT)
Disease/Condition: Brain and Nervous System
Principal Investigator: Nina Kadan-Lottick
A Phase II, Multicenter, Single-Arm Study of MPDL3280A in Patients with PD-L1-Positive Locally Advanced or Metastatic Non-Small Cell Lung Cancer
Disease/Condition: Lung
Principal Investigator: Scott Gettinger
A Phase II/III Randomized Trial of Two Doses of MK-3475 (SCH900475) versus Docetaxel in Previously Treated Subjects with Non-Small Cell Lung Cancer
Disease/Condition: Lung
Principal Investigator: Roy Herbst
A Phase III Randomized Double-Blind Trial of Maintenance with Niraparib Versus Placebo in Patients with Platinum Sensitive Ovarian Cancer
Principal Investigator: Masoud Azodi
A Phase III Randomized Study of Adjuvant Ipilimumab Anti-CTLA4 Therapy Versus High-Dose Interferon a-2b for Resected High-Risk Melanoma (ECOG E1609)
Disease/Condition: Melanoma, skin
Principal Investigator: Harriet Kluger
A Phase III Randomized Trial Comparing Androgen Deprivation Therapy + TAK-700 With Androgen Deprivation Therapy + Bicalutamide in Patients With Newly Diagnosed Metastatic Sensitive Prostate Cancer
Disease/Condition: Prostate
Principal Investigator: Daniel Petrylak
A Phase III Randomized Trial for Patients with de novo AML using Bortezomib and Sorafenib for patients with High Allelic Ratio FLT3/ITD
Disease/Condition: Cancer | Myeloid and Monocytic Leukemia
Principal Investigator: Nina Kadan-Lottick
A Phase III Randomized Trial of Chemoembolization with or without Sorafenib in Unresectable Hepatocellular Carcinoma (HCC) in Patients with and without Vascular Invasion (ECOG 1208)
Disease/Condition: Liver | Liver Cancer
Principal Investigator: Stacey Stein
A Phase III Randomized Trial of Chemotherapy with or without Bevacizumab in Patients with Recurrent or Metastatic Head and Neck Cancer (ECOG E1305)
Disease/Condition: Head and Neck Cancer | Larynx | Lip, Oral Cavity and Pharynx
Principal Investigator: Hari Deshpande
A Phase III Randomized, Placebo-Controlled Clinical Trial Evaluating the Use of Adjuvant Endocrine Therapy +/- One Year of Everolimus in patients with High-Risk, Hormone Receptor-Positive and HER2/neu Negative Breast Cancer
Disease/Condition: Breast - Female | Breast - Male | Cancer
Principal Investigator: Maysa Abu-Khalaf
A Phase III Study of Risk Directed Therapy for Infants with Acute Lymnphoblastic Leukemia (ALL): Randomization of Highest Risk Infants to Intensive Chemotherapy +-FLT3 Inhibition
Disease/Condition: Leukemia, other
Principal Investigator: Nina Kadan-Lottick
A Phase III Trial of Adjuvant Chemotherapy as Primary Treatment for Locally Advanced Cervical Cancer Compared to Chemoradiation Alone: The Outback Trial
Principal Investigator: Peter Schwartz
A Phase III, Randomized Clinical Trial of Standard Adjuvant Endocrine Therapy +/- Chemotherapy in Patients with 1-3 Positive Nodes, Hormone Receptor-Positive and HER-2 Negative Breast Cancer with Recurrence Score (RS) of 25 or Less (SWOG S1007) (CIRB)
Disease/Condition: Breast - Female
Principal Investigator: Erin Hofstatter
A Phase III, Randomized, Double Blind, Placebo Controlled, Multicentre Study of Olaparib Maintenance Monotherapy in Patients with BRCA Mutated Advanced (FIGO Stage III-IV) Ovarian Cancer following First Line Platinum Based Chemotherapy.
Principal Investigator: Thomas Rutherford
A Randomized Controlled Trial of Routine Shave Margins Versus Standard Partial Mastectomy in Breast Cancer Patients
Disease/Condition: Breast - Female | Breast Cancer
Principal Investigator: Anees Chagpar
A Randomized Phase II trial of Neoadjuvant Cisplatin vs. Doxorubicin/Cyclophosphamide (AC) in Women with Newly Diagnosed Breast Cancer and Germline BRCA Mutations
Disease/Condition: Breast - Female | Breast - Male
Principal Investigator: Erin Hofstatter
A Randomized Phase II/III Trial of Surgery and Postoperative Radiation Delivered With Concurrent Cisplatin Versus Docetaxel Versus Docetaxel and Cetuximab for High-Risk Squamous Cell Cancer of the Head and Neck (RTOG 1216)
Principal Investigator: Roy Decker
A Randomized Phase IIB Study of Nivolumab or Nivolumab in Combination with Ipilimumab versus Bevacizumab in Adult Subjects with Recurrent Glioblastoma
Disease/Condition: Brain and Nervous System
Principal Investigator: Joachim Baehring
A Randomized Phase III Clinical Trial Evaluating Post-Mastectomy Chestwall and Regional Nodal XRT and Post-Lumpectomy Regional Nodal XRT in Patients with Positive Axillary Nodes Before Neoadjuvant Chemotherapy Who Convert to Pathologically Negative Axillary Nodes After Neoadjuvant Chemotherapy (NSABP B-51/RTOG 1304)
Disease/Condition: Breast - Female
Principal Investigator: Suzanne Evans
A Randomized Phase III Study Comparing Cabazitaxel/Prednisone in Combination with Custirsen (OGX-011) to Cabazitaxel/Prednisone for Second-Line Chemotherapy in Men with Metastatic Castrate Resistant Prostate Cancer
Disease/Condition: Prostate
Principal Investigator: Daniel Petrylak
A Randomized Phase III Study of Standard Cytarabine Plus Daunomycin (7+3) Therapy versus Idarubicin with High Dose Cytarabine (IA) with or without Vorinostat (IA+V) in Younger Patients with Previously Untreated Acute Myeloid Leukemia (AML)
Disease/Condition: Myeloid and Monocytic Leukemia
Principal Investigator: Nikolai Podoltsev
A Randomized Phase III Trial of Adjuvant Therapy Comparing Chemotherapy Alone (Six Cycles of Docetaxel Plus Cyclophosphamide or Four Cycles of Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel) to Chemotherapy Plus Trastuzumab in Women with Node-Positive or High-Risk Node-Negative HER2-Low Invasive Breast Cancer
Disease/Condition: Breast - Female | Breast Cancer
Principal Investigator: Erin Hofstatter
A Randomized Phase III Trial of Cisplatin and Tumor Volume Directed Irradiation Followed by Carboplatin and Paclitaxel vs. Carboplatin and Paclitaxel for Optimally Debulked, Advanced Endometrial Carcinoma (GOG 0258) (CIRB)
Disease/Condition: Corpus Uteri | Endometrial Cancer
Principal Investigator: Masoud Azodi
A Randomized, Double-Blind, Placebo-Controlled Phase II Study Of Vtx-2337 In Combination With Pegylated Liposomal Doxorubicin (Pld) In Patients With Recurrent Or Persistent Epithelial Ovarian, Fallopian Tube Or Primary Peritoneal Cancer
Principal Investigator: Alessandro Santin
A Randomized, Double-Blind, Placebo-Controlled, Phase III Study to Evaluate the Efficacy and Safety of Afatinib (BIBW 2992) as Adjuvant Therapy After Chemo-Radiotherapy in Primary Unresected Patients with Stage III, IVa, or IVb Loco-Regionally Advanced Head and Neck Squamous Cell Carcinoma
Disease/Condition: Brain and Nervous System | Other Respiratory and Intrathoracic Organs
Principal Investigator: Anne Chiang
A RANDOMIZED, MULTICENTER, ADAPTIVE PHASE II/III STUDY TO EVALUATE THE EFFICACY AND SAFETY OF TRASTUZUMAB EMTANSINE (T-DM1) VERSUS TAXANE (DOCETAXEL OR PACLITAXEL) IN PATIENTS WITH PREVIOUSLY TREATED LOCALLY ADVANCED OR METASTATIC HER2-POSITIVE GASTRIC CANCER, INCLUDING ADENOCARCINOMA OF THE GASTROESOPHAGEAL JUNCTION
Disease/Condition: Adenocarcinoma of the Gastroesophageal Junction | Esophagus | Gastric Cancer | Stomach
Principal Investigator: Howard Hochster
A Randomized, Multicenter, Double-Blind Phase III Study of PD-0332991 Plus Letrozole Versus Placebo Plus Letrozole for the Treatment of Postmenopausal Women with ER (+), HER2 (-) Breast Cancer who have not Received any Prior Systemic Anti-Cancer Treatment for Advanced Disease
Disease/Condition: Breast - Female
Principal Investigator: Maysa Abu-Khalaf
A Randomized, Multicenter, Open-label Phase III Study to Evaluate the Efficacy and Safety of Trastuzumab Emtansine versus Trastuzumab as Adjuvant Therapy for Patients with HER2-Positive Primary Breast Cancer who have Residual Tumor Present Pathologically in the Breast or Axillary Lymph Nodes following Preoperative Therapy (NSABP B50/Katherine Study)
Disease/Condition: Breast - Female | Breast - Male
Principal Investigator: Michael DiGiovanna
A Randomized, Open-Label, Phase II Study of Sipuleucel-T with Concurrent vs Sequential Administration of Enzalutamide in Men with Metastatic Castrate Resistant Prostate Cancer
Disease/Condition: Prostate
Principal Investigator: Daniel Petrylak
A Randomized, Phase 2, Open-Label Study Evaluating DN24-02 as Adjuvant Therapy in Subjects with High Risk HER2+ Urothelial Carcinoma
Disease/Condition: Bladder | Cancer
Principal Investigator: Hari Deshpande
A Single Arm, Neoadjuvant, Phae II Trial of Pertuzumab and Trastuzumab Administered Concomitantly with Weekly Paclitaxel and FEC for Clinical Stage I-III HER2-Positive Breast Cancer
Disease/Condition: Breast - Female
Principal Investigator: Lajos Pusztai
ACRIN 6690: A Prospective, Multicenter Comparison of Multiphase Contrast-Enhanced CT and Multiphase Contrast-Enhanced MRI for Diagnosis of Hepatocellular Carcinoma and Liver Transplant Allocation
Disease/Condition: Liver | Liver Cancer
Principal Investigator: Jeffrey Weinreb
An International, Randomized, Double-Blind, Controlled Study of Rindopepimut/GM-CSF with Adjuvant Temozolomide in Patients with Newly Diagnosed, Surgically Resected, EGFRvIII-positive Glioblastoma
Disease/Condition: Brain and Nervous System | Glioblastoma
Principal Investigator: Kevin Becker
An Open Label, International, Multi-Center, Phase I/IIA Study of Lenalidomide (Revlimid) and Romidepsin (Istodax) for Relapsed/Refractory Hodgkin Lymphoma, Mature T-Cell Lymphoma and Multiple Myeloma (RID Study)
Disease/Condition: Hodgkin's Lymphoma | Multiple Myeloma | Non-Hodgkin's Lymphoma
Principal Investigator: Francine Foss
An Open-label, Multicenter, Randomized Phase II Study Evaluating the Safety and Efficacy of Docetaxel in Combination With IMC 1121B or IMC 18F1 or Without Investigational Therapy as Second line Therapy in Patients With Metastatic Transitional Cell Carcinoma of the Bladder, Urethra, Ureter, or Renal Pelvis Following Disease Progression on First-line Platinum-based Therapy
Disease/Condition: Bladder | Kidney | Other Urinary
Principal Investigator: Daniel Petrylak
An Open-label, Randomized Phase III Study of Inotuzumab Ozogamicin Compared to a Defined Investigator's Choice in Adult Patients with Relapsed or Refractory CD22-Positive Acute Lymphoblastic Leukemia (ALL)
Disease/Condition: Leukemia, other
Principal Investigator: Nikolai Podoltsev
Assessment of the Decision-making Impact of the Breast Cancer Index in Recommending Extended Adjuvant Endocrine Therapy for Patients with Early Stage ER-positive Breast Cancer
Principal Investigator: Tara Sanft
Atypical Lesions of the Breast: Close Observation vs. Excision (ALCOVE)
Principal Investigator: Brigid Killelea
BATTLE-2 Program: A Biomarker-Integrated Targeted Therapy Study
Disease/Condition: Lung | Non Small Cell Lung Cancer
Principal Investigator: Roy Herbst
Carboplatin and Paclitaxel With or Without Bevacizumab and/or Cetuximab in Treating Patients With Stage IV or Recurrent Non-Small Cell Lung Cancer
Disease/Condition: Lung | Lung Cancer | Non Small Cell Lung Cancer
Principal Investigator: Roy Herbst
Characterization of Tumor Cells in the Arterial and Venous Circulations of Non Small Cell Lung Cancer Patients
Disease/Condition: Non Small Cell Lung Cancer
Principal Investigator: Daniel J. Boffa
Chemotherapy Toxicity On Quality of Life in Older Patients With Stage I, Stage II, Stage III, or Stage IV Ovarian Epithelial, Primary Peritoneal Cavity, or Fallopian Tube Cancer
Disease/Condition: Fallopian Tube Cancer | Other Female Genital | Ovarian Cancer | Ovary | Primary Peritoneal Cavity Cancer
Principal Investigator: Thomas Rutherford
Collecting and Storing Tissue, Blood, and Bone Marrow Samples From Patients With Rhabdomyosarcoma or Other Soft Tissue Sarcoma
Disease/Condition: Adult Rhabdomyosarcoma | Childhood Desmoplastic Small Round Cell Tumor | Chordoma | Desmoid Tumor | Metastatic Childhood Soft Tissue Sarcoma | Nonmetastatic Childhood Soft Tissue Sarcoma | Previously Treated Childhood Rhabdomyosarcoma | Previously Untreated Childhood Rhabdomyosarcoma | Recurrent Adult Soft Tissue Sarcoma | Recurrent Childhood Rhabdomyosarcoma | Recurrent Childhood Soft Tissue Sarcoma | Soft Tissue | Stage I Adult Soft Tissue Sarcoma | Stage II Adult Soft Tissue Sarcoma | Stage III Adult Soft Tissue Sarcoma | Stage IV Adult Soft Tissue Sarcoma
Principal Investigator: Nina Kadan-Lottick
Combination Chemotherapy in Treating Patients With Non-Metastatic Extracranial Ewing Sarcoma
Disease/Condition: Adult Supratentorial Primitive Neuroectodermal Tumor (PNET) | Childhood Supratentorial Primitive Neuroectodermal Tumor | Ewing Sarcoma of Bone | Extraosseous Ewing Sarcoma | Extraosseous Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor | Peripheral Primitive Neuroectodermal Tumor of the Kidney | Soft Tissue | Untreated Childhood Supratentorial Primitive Neuroectodermal Tumor
Principal Investigator: Gary Kupfer
Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Liver Cancer
Disease/Condition: Childhood Hepatoblastoma | Liver | Stage I Childhood Liver Cancer | Stage II Childhood Liver Cancer | Stage III Childhood Liver Cancer | Stage IV Childhood Liver Cancer
Principal Investigator: Nina Kadan-Lottick
Defibrotide for Patients with Hepatic Veno-Occlusive Disease (VOD)
Disease/Condition: Hepatic Veno-Occlusive Disease | Hodgkin's Lymphoma | Leukemia, not otherwise specified | Multiple Myeloma | Non-Hodgkin's Lymphoma
Principal Investigator: Stuart Seropian
Examination of Epigenetic Changes in Breast Tissue and Peripheral Blood of Women at Average versus Increased Risk of Breast Cancer
Disease/Condition: Breast Cancer | Cancer
Principal Investigator: Erin Hofstatter
Gemcitabine Hydrochloride and Cisplatin With or Without Bevacizumab in Treating Patients With Advanced Urinary Tract Cancer
Disease/Condition: Bladder | Distal Urethral Cancer | Metastatic Transitional Cell Cancer of the Renal Pelvis and Ureter | Proximal Urethral Cancer | Recurrent Bladder Cancer | Recurrent Prostate Cancer | Recurrent Transitional Cell Cancer of the Renal Pelvis and Ureter | Recurrent Urethral Cancer | Stage IV Bladder Cancer | Stage IV Prostate Cancer | Transitional Cell Carcinoma of the Bladder | Urethral Cancer Associated With Invasive Bladder Cancer
Principal Investigator: Hari Deshpande
Improving Adherence to Oral Cancer Agents and Self Care of Symptoms Using an IVR
Disease/Condition: Cancer
Principal Investigator: Elizabeth Ercolano
IncobotulinumtoxinA for treatment of focal cancer pain after surgery and/or radiation
Disease/Condition: Ill-Defined Sites
Principal Investigator: Bahman Jabbari
Intergroup Trial for Children or Adolescents With B-Cell Non Hodgkin Lymphoma or B-Acute Leukemia: Evaluation of Rituximab Efficacy and Safety in High Risk Patients - Phase III Trial
Disease/Condition: Leukemia, other
Principal Investigator: Nina Kadan-Lottick
Intra-Operative Specimen Imaging in Breast Cancer Patients Undergoing Standard Partial Mastectomy: A Pilot of the Faxitron BioVision Wedge 3D versus BioVision 2D Imaging
Disease/Condition: Breast Cancer | Cancer
Principal Investigator: Anees Chagpar
Longitudinal Assessment and Functional Outcomes in Patients with Hematologic Malignancies and Related Disorders
Disease/Condition: Hematologic Malignancies
Principal Investigator: Stephanie Halene
Maintenance Chemotherapy or Observation Following Induction Chemotherapy and Radiation Therapy in Treating Younger Patients With Newly Diagnosed Ependymoma
Disease/Condition: Brain and Nervous System | Childhood Infratentorial Ependymoma | Childhood Supratentorial Ependymoma | Newly Diagnosed Childhood Ependymoma
Principal Investigator: Nina Kadan-Lottick
Molecular Predictors of Radiation Resistance
Disease/Condition: Unknown Sites
Principal Investigator: Joseph Contessa
Neuroblastoma Antibody Study
Disease/Condition: Brain and Nervous System | Disseminated Neuroblastoma | Localized Resectable Neuroblastoma | Localized Unresectable Neuroblastoma | Regional Neuroblastoma | Stage 4S Neuroblastoma
Principal Investigator: Nina Kadan-Lottick
Newly Diagnosed High Risk B-Precursor ALL - Clofarabine
Disease/Condition: Leukemia, not otherwise specified
Principal Investigator: Nina Kadan-Lottick
Oxaliplatin, Leucovorin Calcium, and Fluorouracil With or Without Celecoxib in Treating Patients With Stage III Colon Cancer Previously Treated With Surgery
Disease/Condition: Colon | Colorectal Cancer
Principal Investigator: Howard Hochster
PET-Directed Therapy in Treating Patients With Limited-Stage Diffuse Large B-Cell Lymphoma
Disease/Condition: Limited-stage Diffuse Large B-Cell Lymphoma | Non-Hodgkin's Lymphoma
Phase Ib Trial of MPDL3280A with Bevacizumab or with Bevacizumab + FOLFOX in Patients with Solid Tumors
Disease/Condition: Colon | Lung | Rectum
Principal Investigator: Howard Hochster
Phase II Ipilimumab Monotherapy in Recurrent Platinum Sensitive Ovarian Cancer
Disease/Condition: Cancer
Principal Investigator: Alessandro Santin
Phase II neoadjuvant vemurafenib trial in melanoma patients with untreated brain metastases with B-raf mutations
Disease/Condition: Cancer | Melanoma, skin
Principal Investigator: Harriet Kluger
Phase II Study of Folfirinox for Advanced Pancreatic Cancer
Disease/Condition: Advanced Pancreatic Cancer | Metastatic Pancreatic Cancer | Pancreas | Pancreatic Cancer
Principal Investigator: Jill Lacy
Phase II Study of Peri-Operative Modified Folfirinox in Localized Pancreatic Cancer
Disease/Condition: Pancreas
Principal Investigator: Jill Lacy
Phase III Study of Postoperative Radiation Therapy (IMRT) +/- Cetuximab for Locally-Advanced Resected Head and Neck Cancer (RTOG 0920) (CIRB)
Disease/Condition: Head and Neck Cancer | Larynx | Lip, Oral Cavity and Pharynx
Principal Investigator: Roy Decker
Pilot study of Image Guided RT for Stage 0 and 1 Breast Study
Disease/Condition: Breast - Female | Breast Cancer
Principal Investigator: Suzanne Evans
Radiation Therapy, Paclitaxel, and Carboplatin With or Without Trastuzumab in Treating Patients With Esophageal Cancer
Disease/Condition: Adenocarcinoma of the Esophagus | Adenocarcinoma of the Gastroesophageal Junction | Esophagus | Stage IB Esophageal Cancer | Stage IIA Esophageal Cancer | Stage IIB Esophageal Cancer | Stage IIIA Esophageal Cancer | Stage IIIB Esophageal Cancer
Principal Investigator: Bryan Chang
Randomized Phase II Trial of PET Scan-Directed Combined Modality Therapy in Esophageal Cancer
Disease/Condition: Esophagus
Principal Investigator: Daniel Boffa
Risk-Adapted Chemotherapy in Younger Patients With Newly Diagnosed Standard-Risk Acute Lymphoblastic Leukemia
Disease/Condition: B-cell Childhood Acute Lymphoblastic Leukemia | Leukemia | Lymphoid Leukemia | Philadelphia Chromosome Positive Adult Precursor Acute Lymphoblastic Leukemia | Untreated Adult Acute Lymphoblastic Leukemia | Untreated Childhood Acute Lymphoblastic Leukemia
Principal Investigator: Nina Kadan-Lottick
Risk-Based Classification System of Patients With Newly Diagnosed Acute Lymphoblastic Leukemia
Disease/Condition: Untreated Adult Acute Lymphoblastic Leukemia | Untreated Childhood Acute Lymphoblastic Leukemia
Principal Investigator: Nina Kadan-Lottick
RTOG 0815: Randomized Trial With or Without Short-Term Androgen Deprivation for Intermediate-Risk Prostate Cancer
Disease/Condition: Prostate | Prostate Cancer
Principal Investigator: Joseph Cardinale
Selective Depletion of CD45RA+T Cells From Allogeneic Peripheral Blood Stem Cell Grafts for the Prevention of GVHD
Disease/Condition: Graft Versus Host Disease | Leukemia, not otherwise specified | Myelodysplastic Syndromes | Non-Hodgkin's Lymphoma
Principal Investigator: Warren Shlomchik
STEAM (Sequencing Triplet with Avastin and Maintenance): Folfoxiri/Bevacizumab Regiments (Concurrent and Sequential) vs. Folfox/Bevacizumab in First-Line Metastatic Colorectal Cancer
Disease/Condition: Colon
Principal Investigator: Howard Hochster
Study of Kidney Tumors in Young Patients
Disease/Condition: Clear Cell Sarcoma of the Kidney | Congenital Mesoblastic Nephroma | Diffuse Hyperplastic Perilobar Nephroblastomatosis | Rhabdoid Tumor of the Kidney | Stage I Renal Cell Cancer | Stage I Wilms Tumor | Stage II Renal Cell Cancer | Stage II Wilms Tumor | Stage III Renal Cell Cancer | Stage III Wilms Tumor | Stage IV Renal Cell Cancer | Stage IV Wilms Tumor | Stage V Wilms Tumor
Principal Investigator: Gary Kupfer
Study of Late-Occurring Complications in Childhood Cancer Survivors
Disease/Condition: Cancer Survivor | Cardiovascular Complications | Hematopoietic/Lymphoid Cancer | Unspecified Childhood Solid Tumor, Protocol Specific
Principal Investigator: Kupfer, Gary
Text Messaging to Improve Adherence to Oral Chemotherapy Agents
Disease/Condition: Cancer
Principal Investigator: Elizabeth Ercolano
The MILO Study (MEK Inhibitor in Low-grade Serous Ovarian Cancer): A Multinational, Randomized, Open-label Phase III Study of MEK162 vs. Physician's Choice of Chemotherapy in Patients with Recurrent or Persistent Low-grade Serous Carcinomas of the Ovary, Fallopian Tube, or Primary Peritoneum
Principal Investigator: Thomas Rutherford
The Preoperative Health and Body (PREHAB) Study
Disease/Condition: Breast - Female
Principal Investigator: Melinda Irwin
V212 (inactivated varicella-zoster virus vaccine) in Adult Patients with Solid Tumor or Hematologic Malignancies
Principal Investigator: Debra Brandt
Yale Pathology Tissue Services (YPTS) Tissue Banking Protocol
Principal Investigator: David Rimm